These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 18611244)

  • 21. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
    Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
    Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
    Patel JR; Banjara B; Ohemeng A; Davidson AM; Boué SM; Burow ME; Tilghman SL
    Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
    Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
    Neville-Webbe HL; Coleman RE; Holen I
    Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system.
    Chimento A; Sirianni R; Zolea F; De Luca A; Lanzino M; Catalano S; Andò S; Pezzi V
    J Cell Physiol; 2012 May; 227(5):2079-88. PubMed ID: 21769864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
    BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.